Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Basit Öğe Kaydı
dc.contributor.authorHacioglu, Muhammet Bekir
dc.contributor.authorKostek, Osman
dc.contributor.authorKarabulut, Senem
dc.contributor.authorTastekin, Didem
dc.contributor.authorGoksu, Sema Sezgin
dc.contributor.authorAlandag, Celal
dc.contributor.authorAkagunduz, Baran
dc.date.accessioned2024-04-24T17:33:46Z
dc.date.available2024-04-24T17:33:46Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib.en_US
dc.identifier.endpage1903en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue4en_US
dc.identifier.pmid33099930
dc.identifier.scopus2-s2.0-85090483650
dc.identifier.scopusqualityQ3
dc.identifier.startpage1897en_US
dc.identifier.urihttps://hdl.handle.net/11468/20836
dc.identifier.volume25en_US
dc.identifier.wosWOS:000573102800001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buon
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatocellular Carcinomaen_US
dc.subjectRegorafeniben_US
dc.subjectDisease Control Rateen_US
dc.subjectOverall Survivalen_US
dc.subjectChemotherapyen_US
dc.subjectAnti-Vegf Therapyen_US
dc.titleEfficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkeyen_US
dc.titleEfficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu